Floatz logo

Hydroxyurea

Spinal Muscular Atrophy

Kaohsiung Medical University Chung-Ho Memorial HospitalSmall moleculePhase 2/3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Spinal Muscular Atrophy cohort.

Asset / SponsorPhaseRating
Nusinersen
Scholar Rock, Inc.
Phase 4A
Risdiplam
Scholar Rock, Inc.
Phase 4A
Non-Replicating Recombinant Self-Complementary (Sc) Adeno-Associated Virus Serotype 9 (Aav9) Vector Containing The Cdna Of The Survival Of Motor Neuron 2 (Smn2) Gene Under The Control Of The Hybrid Cytomegalovirus (Cmv) Enhancer/Chicken Beta-Actin Promoter (Cba)
Novartis Pharmaceuticals
Phase 4BBB
oav101
Novartis Pharmaceuticals
Phase 4BBB
Apitegromab
Scholar Rock, Inc.
Phase 3BB

View all 38 →

Same molecule, other indications

Hydroxyurea is also rated in:

beta-thalassemia majorActive
BBB
Indicative · Phase 4
77 / 100
View asset →
sickle cell diseaseActive
BB
Indicative · Phase 4
71 / 100
View asset →
thalassemiaActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →